Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ApexOnco Front Page
Recent articles
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Big pharma interest remains, but the mood is fast turning gloomy.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
After menin, the company tries again with farnesyl transferase.
